CG Therapeutics, Inc. (CGT) is a biotechnology company focused on commercializing cancer therapies that neutralize a key hormone produced by tumors: human chorionic gonadotropin (hCG). hCG, and its variants, play important roles in promoting the growth and spread of cancer.

Phase 2 clinical trials already conducted with a prototype of the company’s first product, the anti-hCG vaccine CG201, have demonstrated its ability to neutralize hCG and increase patient survival without significant side effects.